Clinical Trials
10 trialsNCT06172296 2026-06-03
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT04514497 2026-06-02
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02567435 2026-05-27
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06995872 2026-05-22
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT02890355 2026-05-20
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02595931 2026-05-13
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT00980460 2026-05-04
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00045201 2026-04-13
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03641313 2026-04-13
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03366155 2026-01-08
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed